Partner since 2022: For moderate-to-refractory open-angle glaucoma when medications and/or angle-based MIGS are insufficient, offering a bleb-forming alternative to trabeculectomy and tubes like Baerveldt—while aiming to balance efficacy and early-postop safety. for markets outside NWM.